Tissue plasminogen activator to treat impending pupillary block glaucoma in patients with acute fibrinous HLA-B27 positive iridocyclitis

American Journal of Ophthalmology

Volumn 129, Issue 3, 2000, Pages 363-366

  Skolnick, Craig A ^a   Fiscella, Richard G ^a,b   Tessler, Howard H ^a   Goldstein, Debra A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b College of Pharmacy ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B27 ANTIGEN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CASE REPORT; CORNEA LIMBUS; DRUG EFFECT; DRUG SCREENING; GLAUCOMA; HLA SYSTEM; HUMAN; IRIDECTOMY; IRIDOCYCLITIS; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; FIBRIN; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; GLAUCOMA; HLA-B27 ANTIGEN; HUMANS; IRIDOCYCLITIS; MALE; PUPIL DISORDERS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0034002668     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(99)00350-5     Document Type: Article

References (12)

1. Jaffe G.J., Abrams G.W., Williams G.A., Han D.P. Tissue plasminogen activator for postvitrecomy fibrin formation. Ophthalmology. 97:1990;184-189.
2. Moon J., Chung S., Myong Y., et al. Treatment of postcataract fibrinous membranes with tissue plasminogen activator. Ophthalmology. 99:1992;1256-1259.
3. Lundy D.C., Sidoti P., Winarko T., Minckler D., Heuer D.K. Intracameral tissue plasminogen activator after glaucoma surgery indications, effectiveness, and complications . Ophthalmology. 103:1996;274-282.
4. Tripathi R.C., Tripathi B.J., Park J.K., et al. Intracameral tissue plasminogen activator for resolution of fibrin clots after glaucoma filtering procedures. Am J Ophthalmol. 111:1991;247-248.
5. Humayun M., Lewis H., Flynn H.W., Sternberg P. Jr, Blumenkranz M.S. Management of submacular hemorrhage associated with retinal arterial macroaneurysms. Am J Ophthalmol. 126:1998;358-361.
6. Saika S., Yamanaka A., Yamanaka A., et al. Subretinal administration of tissue-type plasminogen activator to speed the drainage of subretinal hemorrhage. Graefes Arch Clin Exp Ophthalmol. 236:1998;196-201.
7. Kim M.H., Koo T.H., Sah W.J., Chung S.M. Treatment of total hyphema with relatively low-dose tissue plasminogen activator. Ophthalmic Surg Lasers. 29:1998;762-766.
8. Elman M.J. Thrombolytic therapy for central retinal vein occlusion results of a pilot study . Trans Am Ophthalmol Soc. 94:1996;471-504.
9. Weiss J.N. Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein. Am J Ophthalmol. 126:1998;142-144.
10. Wollensak G, Meyer JH, Loffler KU, Funk J. [Band-like keratopathy after treatment of postoperative fibrin reaction with tissue plasmingen activator] Klin Monatsbl Augenheilkd 1996;209:43-46.
11. Jaffe G.J., Green D.J., Abrams G.W. Stability of recombinant tissue plasminogen activator. Am J Ophthalmol. 108:1989;90-91.
12. Ward C., Weck S. Dilution and storage of recombinant tissue plasminogen activator (Activase) in balanced salt solution. Am J Ophthalmol. 109:1990;98-99.